SCHEMBL4699104

SCHEMBL4699104

COc1ccc2c(c1)c1c(n2C)-c2cnc(C)n2CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
HSD17B10 Q99714 4/20 0.47
DRD2 P14416 1/20 0.46
DRD1 P21728 1/20 0.46
DRD5 P21918 1/20 0.46
DRD3 P35462 1/20 0.46
HTR5A P47898 1/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
MAOA P21397 2/20 0.43
ALDH1A1 P00352 4/20 0.41
HPGD P15428 3/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PDE5A O76074 4/20 0.40
NPC1 O15118 1/20 0.39
ESR1 P03372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4698526 0.93 HSD17B10 (0.42) KDM4EHSD17B10DRD2DRD1DRD5
SCHEMBL4700628 0.85 ACHE (0.36) KDM4EHSD17B10DRD2DRD1DRD5
SCHEMBL14345923 0.84 KDM4E (0.44) KDM4EHSD17B10DRD2DRD1DRD5
Methane SCHEMBL5632637 0.83 KDM4E (0.43) KDM4EHSD17B10DRD2DRD1DRD5
SCHEMBL14425146 0.81 MAOA (0.46) HTR5AMAOAALDH1A1MAPTPDE5A
SCHEMBL4701769 0.80 KDM4E (0.46) KDM4EHSD17B10DRD2DRD3HTR5A
SCHEMBL4702160 0.79 ALOX15 (0.41) KDM4EHSD17B10DRD2DRD1DRD5
SCHEMBL4702510 0.79 BAZ2B (0.41) KDM4EHSD17B10HTR5AACHEMAOA
SCHEMBL4699549 0.78 KDM4E (0.35) KDM4EHSD17B10HTR5AALDH1A1HPGD
SCHEMBL14345729 0.76 DRD2 (0.43) KDM4EHSD17B10DRD2DRD1DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390367-B1 DIHYDROIMIDAZO 5,1-A -$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE MACEF (FR) 2008-07-09 EP disclosed
US-7291627-B2 Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug MACEF (FR) 2007-11-06 US disclosed
US-20060089372-A1 Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine MACEF (FR) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089372-A1 Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine GDI2, GDI1, CYP2A7 KDM4E 2939/4885HSD17B10 511/4885DRD2 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.